Speaker Profile
Ph.D., Founding CEO, Darmiyan
Biography
Padideh Kamali-Zare, PhD, is the Founder and CEO of Darmiyan—the company behind BrainSee.
A computational neuroscientist by training, Padideh’s work has focused on the microstructural architecture of brain tissue and the role of the “space in-between” brain cells in health and disease. She has pioneered methods to translate foundational microstructural biology into clinical insight at population scale.
Padideh has been internationally recognized for her scientific and entrepreneurial contributions and is leading the next frontier of precision brain health and preventive neurology.
Talk
BrainSee Reveals Hidden Biology in Brain MRI
BrainSee is a biologically grounded, microstructure-based intelligence layer built on top of routine MRI, opening the door to true precision brain health and preventive neurology. BrainSee's first FDA-approved clinical application predicts the actionable and modifiable risk of developing Alzheimer’s within 5 years, supporting earlier, targeted interventions that can prevent or delay the onset of dementia.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins University
PMWC Award Ceremony
• Daniel De Carvalho, University of Toronto
From Mutation to Methylation: The Next Wave of Liquid Biopsy Biomarkers
• Chair: Victor Velculescu, Johns Hopkins University
• Daniel De Carvalho, University of Toronto
• Stephen Master, CHOP/U Penn
• Gordon Sanghera, Oxford Nanopore Technologies
Advancing Minimal Residual Disease Detection Through cfDNA & cfRNA Profiling
• Chair: Luis Diaz, Memorial Sloan Kettering Cancer Center
• Anne-Renee Hartman, Adela
• Minetta Liu, Natera
• Rita Shaknovich, Agilent
• Ajay Gannerkote, Integrated DNA Tech
AI-Informed Biomarker Trials: Turning Early Signals into Actionable Designs
• Chair: Manish Kohli, University of Utah
• Eric Klein, GRAIL
• Sarah Moseley, DELFI Diagnostics
• Samuel Levy, ClearNote Health
Role of AI in Liquid Biopsies & Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
• Ron Andrews, Dxcover
• Pankaj Vats, NVIDIA
• Paul Shi, Amgen
• Christopher Troll, Claret Bioscience
Integrating Genetic Risk with Early Detection: A Precision Prevention Framework for Cardiovascular Disease
• Paolo Di Domenico, Allelica
AI-Driven Metagenomic and Host RNA Profiling for Precision Diagnosis of Infections
• Charles Chiu, UCSF
AI-Driven Host–Pathogen Signatures from Plasma cfDNA: Bridging Infection Biology and Early Diagnostics
• Sivan Bercovici, Karius
Ultra-Sensitive Multimodal Liquid Biopsy for Early Cancer Detection: AI-Driven Signal Profiling
• John Sninsky, CellMax Life
Overcoming Limits of Traditional cfDNA Assays Using Active Chromatin
• Diana Abdueva, Aqtual
Whole-genome methylome-based early cancer signal detection
• Sally Mackenzie, EpiMethyl Analytics
BrainSee Sees the Brain: FDA-Approved AI for Predicting Modifiable Risk of Developing Alzheimer’s Within Five Year
• Padideh Kamali-Zare, Darmiyan
